BRCA1 and cancer: Hence, aberrations within the HRR pathway, particularly germline or somatic deleterious mutations in Breast cancer gene-1 (BRCA1) BRCA1 or Breast cancer gene-2(BRCA2), can result in synthetic lethality in the presence of PARP inhibitors [7].